Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab + AVD in pediatric cHL
NCT06848569Phase 2Recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Oct 2024
- Primary completion
- Oct 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of sintilimab in classical Hodgkin lymphoma (cHL), sponsored by Sun Yat-sen University. Started Oct 2024; status: recruiting.
02
Drugs
sintilimab
03
Conditions
classical Hodgkin lymphoma (cHL)
Beyond the preview
Go deeper on NCT06848569.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06848569.